This video segment explores how to choose between the original brand, generic, and micronized versions of abiraterone, considering factors like efficacy, cost, patient preference, and clinical context ...

"This study provides a comprehensive review of the role of natural products as complementary treatments for prostate cancer," says Channing J. Paller, MD. In this video, Channing J. Paller, MD, gives ...

“They come out of the fellowship competent and competitive in the field to any urology position that they're interested in,” says Tania Solomon, PA-C, MSc. In this video, Tania Solomon, PA-C, MSc, ...

“Then recently, of course, with the single-port device, that has truly allowed us to be less invasive with our robotic approaches,” says Adam Lorentz, MD, FACS. In this video, Adam Lorentz, MD, FACS, ...

"If you can do this surgery well, patients actually go back to living a normal life, and they're immensely, immensely happy," says Jaspreet S. Sandhu, MD. In this video, Jaspreet S. Sandhu, MD, ...

"I know this year we're going to see even more companies producing more products, more results, and hopefully really help change and improve patient outcomes, especially when it comes to overactive ...

What is your approach to discussing treatment options with patients, especially when considering the long-term financial impact of different therapies? With all the available treatments on market, ...

Illuccix is approved in Europe for PSMA-positive lesion detection in prostate cancer, following prior approvals in the US, Australia, and Canada. The phase 3 VISION trial showed 177Lu-PSMA-617 plus ...

UGN-101 showed a 68% three-year RFS rate in low-grade UTUC patients, with a median follow-up of 23.5 months. Maintenance therapy significantly improved RFS, but further studies are needed to confirm ...

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life ...

"My biggest hope for people reading this review is to understand that there are some golden opportunities for research," says Laura Bukavina, MD, MPH, MSc. Isali: I think our review mainly highlighted ...

Annual cost analyses suggest that some newer therapies may have higher up-front costs but can be more economical in the long run due to fewer recurrences and less frequent administration. How does the ...